

Exhibit H

Case 1:19-md-02875-RMB-SAK Document 1011-8 Filed 03/09/21 Page 2 of 12 PageID: 22526

	CUSTODIAN	DUPLICATE CUSTODIANS	FROM	TO	CC	SUBJECT	DATE SENT	FILENAME	DOCUMENT DATE	DATE CREATED	FILE TYPE	BASIS FOR WITHHOLDING	DESCRIPTION
1	GE_Jucai	GE_Jucai						3-上海药监局 张清.pdf	6/26/2019	6/20/2019	Portable Document Format	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Summary sheet of information concerning drug marketing licenses provided from Shanghai Municipal Drug Administration
2	TIAN_Sophie	TIAN_Sophie	Eric Tsai <eric6554@hotmail.com>	David Zhao <david.zhao@prinburybiopharm.com> > Luke (Yulu) Wang (Huahai) <luke.wang@huahaipharmus.com> Shu Ye <tree.ye@prinburybiopharm.com> sophie.tian <sophie.tian@prinburybiopharm.com>		Fw: 缬沙坦答补信息	5/16/2017	Fw: 缬沙坦答补信息	5/16/2017	5/18/2017	Microsoft Outlook Note	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	An email discussing the reply to the opinion on the valsartan project from Center for Drug Evaluation (CDE) of the China National Medical Products Administration, in which the CDE expressly required the Company to keep confidential.
3	TIAN_Sophie	LIN_Lihong TIAN_Sophie						2017年6月12日CDE与华海团队交流情况纪要_June_30,2017--CDE修改2.docx	7/9/2017		Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Meeting minutes of a meeting dated 12 June 2017 between ZHP and Chinese Center for Drug Evaluaion regarding improving the quality of the product and register to the Center for Drug Evaluation (CDE) of the China National Medical Products Administration.
4	TIAN_Sophie	LIN_Lihong TIAN_Sophie						2017年6月12日CDE与华海团队交流情况纪要_June_30,2017--CDE修改.docx	7/7/2017		Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Meeting minutes of a meeting dated 12 June 2017 between ZHP and Chinese Center for Drug Evaluaion regarding improving the quality of the product and register to the Center for Drug Evaluation (CDE) of the China National Medical Products Administration.
5	TIAN_Sophie	TIAN_Sophie						2017年6月12日CDE与华海团队交流情况纪要_June_30,2017--CDE修改.docx	7/7/2017	9/29/2017	Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Meeting minutes of a meeting dated 12 June 2017 between ZHP and Chinese Center for Drug Evaluaion regarding improving the quality of the product and register to the Center for Drug Evaluation (CDE) of the China National Medical Products Administration.
6	LIU_Tina	LIU_Tina	Sophie Tian <sophie.tian@prinburybiopharm.com>	Tina Liu <tina.liu@prinburybiopharm.com>		转发: 缬沙坦答补信息	5/16/2017	转发: 缬沙坦答补信息	5/16/2017	6/6/2017	Microsoft Outlook Note	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	An email discussing the reply to the opinion on the valsartan project from Center for Drug Evaluation (CDE) of the China National Medical Products Administration, in which the CDE expressly required the Company to keep confidential.
7	HUANG_Luning	HUANG_Luning ZHU_Wenquan						药物中亚硝胺杂质研究技术指导原则(草稿).pdf	11/18/2019	3/23/2020	Portable Document Format	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	A guideline for the study of nitrosamine impurities in drugs from Center for Drug Evaluation (CDE) of the China National Medical Products Administration, in which the CDE expressly required the Company to keep confidential.
8	TSAI_Eric	TSAI_Eric						缬沙坦片缺陷信答复内部交流会议纪要-2017.05.31.pdf	6/1/2017	5/18/2017	Portable Document Format	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	ZHP meeting minutes, discussing the plan to communicate with CDE regarding to the reply of valsartan tablet deficiency letter.

Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets.
Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China
Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.

16	LIN_Lihong	LIN_Lihong ZHOU_Ting				市海模板	会议纪要_厄贝沙坦CDE交流_20190619.docx	6/28/2019	6/28/2019	Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Meeting minutes concerning irbesartan with Center for Drug Evaluation (CDE) of the China National Medical Products Administration.
17	LIN_Lihong	LIN_Lihong				华海模板	会议纪要_厄贝沙坦CDE交流_20190619.docx	6/28/2019	6/28/2019	Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Meeting minutes for the meeting concerning irbesartan with Center for Drug Evaluation (CDE) of the China National Medical Products Administration
18	LIN_Lihong	LIN_Lihong					Microsoft_Word__11.docx	1/18/2019		Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information	Meeting minutes with National Medical Products Administration and Zhejiang Medical Products Administration, concerning feedbacks of a inspection on ZHP site.
19	LIN_Lihong	LIN_Lihong					厄贝沙坦CDE沟通会.docx	5/10/2019	5/10/2019	Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	A note of key issues for the meeting concerning irbesartan with Center for Drug Evaluation (CDE) of the China National Medical Products Administration.
20	LIN_Lihong	LIN_Lihong					国家规定NDMA_huahai.pdf	7/14/2018	4/3/2019	Portable Document Format	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	A letter concerning assessment of the control of NDMA impurities in the production process from Center for Drug Evaluation (CDE) of the China National Medical Products Administration, in which the CDE expressly required to keep confidential.
21	LIN_Lihong	LIN_Lihong					关于缬沙坦原料药中检出微量亚硝基二甲胺杂质的的情况汇报7.12（国家食品药品监督管理局）_马旺.docx	7/14/2018	4/3/2019	Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	A report on the detection of NDMA impurities in the valsartan API, prepared to send to National Medical Products Administration.
22	LIN_Lihong	LIN_Lihong					2017年6月12日CDE与华海团队交流情况纪要_July 27,2017.docx	7/27/2017	7/27/2017	Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Meeting minutes concerning improving the quality of drugs with Center for Drug Evaluation (CDE) of the China National Medical Products Administration dated June 12, 2017.
23	LIN_Lihong	LIN_Lihong					2017年6月12日CDE与华海团队交流情况纪要_June_30,2017--CDE修改.docx	7/10/2017	7/7/2017	Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Meeting minutes concerning improving the quality of drugs with Center for Drug Evaluation (CDE) of the China National Medical Products Administration dated June 12, 2017.

24	LIN_Lihong	LIN_Lihong						2017年6月12日CDE与华海团队交流情况纪要_June 28,2017.docx	6/28/2017	6/28/2017	Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Meeting minutes concerning improving the quality of drugs with Center for Drug Evaluation (CDE) of the China National Medical Products Administration dated June 12, 2017.
25	LIN_Lihong	LIN_Lihong						2017年6月12日CDE与华海团队交流情况纪要_June 30,2017.docx	6/30/2017	6/30/2017	Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Meeting minutes concerning improving the quality of drugs with Center for Drug Evaluation (CDE) of the China National Medical Products Administration dated June 12, 2017.
26	LIN_Lihong	LIN_Lihong						2017年6月12日CDE与华海团队交流情况纪要_完整版--mw.docx	6/28/2017	6/28/2017	Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information	Meeting minutes for the meeting concerning improving the quality of drugs with Center for Drug Evaluation (CDE) of the China National Medical Products Administration dated June 12, 2017.
27	LIN_Lihong	LIN_Lihong						2017年6月12日CDE与华海团队交流情况纪要_完整版.docx	6/26/2017	6/13/2017	Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information	Meeting minutes for the meeting concerning improving the quality of drugs with Center for Drug Evaluation (CDE) of the China National Medical Products Administration dated June 12, 2017.
28	LIN_Lihong	LIN_Lihong						2018.07.14 山东益健-药品生产日常监督检查报告.jpg	7/16/2018	7/16/2018	JPEG/JFIF Image	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	A daily inspection report on drug production of Shandong Yijian made by Jining Administration for Market Regulation.
29	LIN_Lihong	LIN_Lihong	陈时飞 <csfda@163.com>	林丽红(华海药业) <lindalin@huahaipharm.com>		Re:8个问题_V11	7/31/2018	Re_8个问题_V11.eml	7/31/2018		RFC822 Email Message	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Email with the Direct General of China's Food and Drug Administration of Zhejiang Province regarding the announcement of NDMA in valsartan
30	LIN_Lihong	LIN_Lihong YE_Cunxiao	lindalin@huahaipharm.com	csfda <csfda@163.com>		回复: Re: 10个问题_V10	7/29/2018	回复_Re_10个问题_V10.eml	7/29/2018		RFC822 Email Message	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Email with the Direct General of China's Food And Drug Administration of Zhejiang Province regarding the announcement of NDMA in valsartan
31	LIN_Lihong	LIN_Lihong	陈时飞 <csfda@163.com>	林丽红(华海药业) <lindalin@huahaipharm.com>		Re:回复: 回复: 10个问题_V7	7/29/2018	Re_回复_回复_10个问题_V7.eml	7/29/2018		RPC822 Email Message	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Email with the Direct General of China's Food and Drug Administration of Zhejiang Province regarding the announcement of NDMA in valsartan
32	LIN_Lihong	LIN_Lihong	lindalin@huahaipharm.com	csfda <csfda@163.com>		回复: 回复: 10个问题	7/29/2018	回复_回复_10个问题.eml	7/29/2018		RFC822 Email Message	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Email with the Direct General of China's Food and Drug Administration of Zhejiang Province regarding the announcement of NDMA in valsartan

33	LIN_Lihong	LIN_Lihong	lindalin@huahaipharm.com	csfda <csfda@163.com>		浙江省局关注问题答复2018-5-19	1/16/2019	浙江省局关注问题答复2018-5-19	5/20/2018		RFC822 Email Message	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	ZHP's response to questions raised by Zhejiang Medical Products Administration
34	LIN_Lihong	LIN_Lihong ZHOU_Ting	lindalin@huahaipharm.com	adazhou <adazhou@huahaipharm.com>		Pw: 转发：华海药业关于厄贝沙坦原料药的答复	5/21/2019	Fw: 转发：华海药业关于厄贝沙坦原料药的答复.eml	5/21/2019		RFC822 Email Message	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Email from Center of Drug Evaluation regarding the evaluation of irbesartan API
35	LIN_Lihong	LIN_Lihong	xubo@huahaipharm.com	Linda Lin <lindalin@huahaipharm.com>		转发：华海药业关于厄贝沙坦原料药的答复	5/21/2019	转发：华海药业关于厄贝沙坦原料药的答复.eml	5/21/2019		RFC822 Email Message	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Email from Center of Drug Evaluation regarding the evaluation of irbesartan API
36	LIN_Lihong	LIN_Lihong	xubotj@126.com	Linda Lin <lindalin@huahaipharm.com>		转发：拟召开关于厄贝沙坦原料药沟通交流会，问题详见邮件，请尽快准备并确定参会时间。	5/6/2019	转发：拟召开关于厄贝沙坦原料药沟通交流会，问题详见邮件，请尽快准备并确定参会时间。.eml	5/6/2019		RFC822 Email Message	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Email from Center of Drug Evaluation (CDE) regarding the meeting with ZHP and the preparation of documents relating to the questions raised by CDE
37	LIN_Lihong	LIN_Lihong						省局公函（省局给CDE）.pdf	1/16/2020		Unknown Binary File	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Official letters from ZHP to Zhejiang Drug Administration and Zhejiang Drug Administration to Center of Drug Evaluation of the National Drug Administration regarding the examination and approval of valsartan tablets
38	LIN_Lihong	LIN_Lihong	lindalin@huahaipharm.com	高爱凤 <gaoaifeng@huahaipharm.com>	yangkun@huahaipharm.com	转发: 缙沙坦答补信息	5/25/2017	转发_缙沙坦答补信息 (1).eml	5/25/2017		RFC822 Email Message	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	An email discussing the reply to the opinion on the valsartan project from Center for Drug Evaluation (CDE) of the China National Medical Products Administration, in which the CDE expressly required the Company to keep confidential.
39	LIN_Lihong	LIN_Lihong	lindalin@huahaipharm.com	xubo <xubo@huahaipharm.com>	JohnHu <john.hu@huahaipharmus.com> mawang <mawang@huahaipharm.com>	回复: 答复: 2017年6月12日CDE与华海团队交流情况纪要_June 30, 2017	6/30/2017	回复_答复_2017年6月12日CDE与华海团队交流情况纪要_June 30, 2017.eml	6/30/2017		RFC822 Email Message	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Communications regarding the meeting between ZHP and the officials from Center of Drug Evaluation on the specification and exemption of products dated June 12, 2017
40	LIN_Lihong	LIN_Lihong						2017年6月12日CDE与华海团队交流情况纪要_June 30,2017.docx	6/30/2017		Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Meeting minutes between ZHP and the officials from Center of Drug Evaluation regarding dissolution test and exemption of products dated June 12, 2017
41	LIN_Lihong	LIN_Lihong	lindalin@huahaipharm.com	mawang <mawang@huahaipharm.com>		回复: 回复: 2017年6月12日CDE与华海团队交流情况纪要_简版1	6/30/2017	回复_回复_2017年6月12日CDE与华海团队交流情况纪要_简版1 (2).eml	6/30/2017		RPC822 Email Message	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Communications regarding the Meeting between ZHP and the officials from Center of Drug Evaluation on the specification and exemption of products dated June 12, 2017

42	LIN_Lihong	LIN_Lihong	lindalin@huahaipharm.com	JohnHu <john.hu@huahaipharmus.com> mawang <mawang@huahaipharm.com> xubo <xubo@huahaipharm.com>		回复_答复: 2017年6月12日CDE与华海团队交流 情况纪要_简版1	6/28/2017	回复_答复 2017年6月12日CDE与华海团队交流 情况纪要_简版1 (2).eml	6/28/2017		RPC822 Email Message	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Communication regarding the Meeting between ZHP and the officials from Center of Drug Evalutaion on the specification and examption of products dated June 12, 2017
43	LIN_Lihong	LIN_Lihong	lindalin@huahaipharm.com	mawang <mawang@huahaipharm.com> xubo <xubo@huahaipharm.com>	JohnHu <john.hu@huahaipharmus.com>	回复: 回复: 2017年6月12日CDE与华海团队交流 情况纪要_简版1	6/28/2017	回复_回复 2017年6月12日CDE与华海团队交流 情况纪要_简版1 (5).eml	6/28/2017		RPC822 Email Message	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Meeting minutes between ZHP and the officials from Center of Drug Evaluation regarding dissolution test and exemption of products dated June 12, 2017
44	LIN_Lihong	LIN_Lihong	mawang@huahaipharm.com	徐波 <xubo@huahaipharm.com> 林丽红Linda <lindalin@huahaipharm.com>	JH <john.hu@huahaipharmus.com>	回复: 2017年6月12日CDE与华海团队交流 情况纪要_简版1	6/28/2017	回复 2017年6月12日CDE与华海团队交流 情况纪要_简版1.eml	6/28/2017		RPC822 Email Message	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Communications regarding the meeting between ZHP and the officials from Center of Drug Evaluation on the specification and exemption of products dated June 12, 2017
45	LIN_Lihong	LIN_Lihong						2017年6月12日CDE与华海团队交流 情况纪要_June 28,2017.docx	6/28/2017		Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Meeting minutes between ZHP and the officials from Center of Drug Evaluation regarding dissolution test and exemption of products dated June 12, 2017
46	LIN_Lihong	LIN_Lihong						2017年6月12日CDE与华海团队交流 情况纪要_June_30,2017-- CDE修改.docx	7/8/2017		Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Meeting minutes between ZHP and the officials from Center of Drug Evaluation regarding dissolution test and exemption of products dated June 12, 2017
47	LIN_Lihong	LIN_Lihong						2017年6月12日CDE与华海团队交流 情况纪要_June_30,2017--修改.docx	7/7/2017		Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Meeting minutes between ZHP and the officials from Center of Drug Evaluation regarding dissolution test and exemption of products dated June 12, 2017
48	LIN_Lihong	LIN_Lihong						2017年6月12日CDE与华海团队交流 情况纪要_July 272017 修改胡.docx	7/28/2017		Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Meeting minutes between ZHP and the officials from Center of Drug Evaluation regarding dissolution test and exemption of products dated June 12, 2017

49	LIN_Lihong	LIN_Lihong						2017年6月12日CDE与华海团队交流情况纪要_July 27,2017.docx	7/27/2017		Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Meeting minutes between ZHP and the officials from Center of Drug Evaluation regarding dissolution test and exemption of products dated June 12, 2017
50	LIN_Lihong	LIN_Lihong						2017年6月12日CDE与华海团队交流情况纪要_July 27,2017.docx	7/27/2017		Unknown Binary File	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Meeting minutes between ZHP and the officials from Center of Drug Evaluation regarding dissolution test and exemption of products dated June 12, 2017
51	LIN_Lihong	LIN_Lihong						2017年6月12日CDE与华海团队交流情况纪要_June_30,2017--CDE修改.docx	7/25/2017		Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Meeting minutes between ZHP and the officials from Center of Drug Evaluation regarding dissolution test and exemption of products dated June 12, 2017
51	LIN_Lihong	LIN_Lihong	david.zhao@prinburybiopharm.com	lindalin@huahaipharm.com 高爱凤 <gaoaifeng@huahaipharm.com>	wangjuan <wangjuan@huahaipharm.com>	RE: 回复: 2017年6月12日CDE与华海团队交流情况纪要_June 30, 2017	7/25/2017	RE_回复_ 2017年6月12日CDE与华海团队交流情况纪要_June 30, 2017.eml	7/25/2017		RFC822 Email Message	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Meeting minutes between ZHP and the officials from Center of Drug Evaluation regarding dissolution test and exemption of products dated June 12, 2017
53	LIN_Lihong	LIN_Lihong	lindalin@huahaipharm.com	高爱凤 <gaoaifeng@huahaipharm.com>	David Zhao <david.zhao@prinburybiopharm.com> > wangjuan <wangjuan@huahaipharm.com>	转发: 回复: 2017年6月12日CDE与华海团队交流情况纪要_June 30, 2017	7/25/2017	转发_回复_ 2017年6月12日CDE与华海团队交流情况纪要_June 30, 2017.eml	7/25/2017		RFC822 Email Message	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Summary of meeting between ZHP and the officials from Center of Drug Evaluation on the specification and exemption of products dated June 12, 2017
54	LIN_Lihong	LIN_Lihong						2017年6月12日CDE与华海团队交流情况纪要_June 30,2017.docx	7/25/2017		Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Meeting minutes between ZHP and the officials from Center of Drug Evaluation regarding dissolution test and exemption of products dated June 12, 2017
55	LIN_Lihong	LIN_Lihong						2017年6月12日CDE与华海团队交流情况纪要_June 30,2017.docx	10/19/2017		Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Meeting minutes between ZHP and the officials from Center of Drug Evaluation regarding dissolution test and exemption of products dated June 12, 2017

56	LIN_Lihong	LIN_Lihong										Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Summary of the reports provided to the authorities
57	LIN_Lihong	LIN_Lihong	林丽红 <lindalin@huahaipharm.com>	陈时飞 <csfda@163.com>		Re: Re:8个问题_V11	7/31/2018	Re_Re_8个问题_V11.eml	7/31/2018			RFC822 Email Message	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Email with the Direct General of China's Food and Drug Administration of Zhejiang Province regarding the announcement of NDMA in valsartan
58	LIN_Lihong	LIN_Lihong	lindalin@huahaipharm.com	csfda <csfda@163.com>		回复: 回复: 10个问题_V7	7/29/2018	回复_回复_10个问题_V7.eml	7/29/2018			RFC822 Email Message	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Email with the Direct General of China's Food And Drug Administration of Zhejiang Province regarding the announcement of NDMA in valsartan
59	LIN_Lihong	LIN_Lihong	lindalin@huahaipharm.com	csfda <csfda@163.com>		回复: 回复: 10个问题	7/29/2018	回复_回复_10个问题 (1).eml	7/29/2018			RFC822 Email Message	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Email with the Direct General of China's Food and Drug Administration of Zhejiang Province regarding the announcement of NDMA in valsartan
60	LIN_Lihong	LIN_Lihong YE_Cunxiao	lindalin@huahaipharm.com	csfda <csfda@163.com>		回复: 10个问题	7/29/2018	回复_10个问题.eml	7/29/2018			RPC822 Email Message	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Email with the Direct General of China's Food and Drug Administration of Zhejiang Province regarding the announcement of NDMA in valsartan
61	LIN_Lihong	LIN_Lihong						浙华药字【2020】1号.doc	5/7/2020			Unknown Binary File	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	A report intended for Zhejiang Medical Products Administration requesting guidance on data protection law.
62	CHEN_Baozhenn	CHEN_Baozhenn YE_Cunxiao				新文档 2018-08-15 13.56.27		召回审查和评价结论（省局20180809红头文件）.pdf	8/15/2018	8/20/2018		Portable Document Format	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Document from Zhejiang Medical Products Administration to ZHP regarding the conclusion of recall review and appraisal
63	CHEN_Baozhenn	CHEN_Baozhenn						召回评估报告手打版.docx	8/3/2018	8/20/2018		Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	A report from Zhejiang Medical Products Administration to ZHP regarding the conclusion of recall review and appraisal
64	CHEN_Baozhenn	CHEN_Baozhenn						浙江省食品药品监督管理局现场有因检查报告2018.08.01-03word版.doc	8/3/2018	8/4/2018		Microsoft Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	A report from Zhejiang Medical Products Administration to ZHP regarding on-site inspection
65	CHEN_Baozhenn	CHEN_Baozhenn						20190110-专家组检查清单汇总(1).docx	1/11/2019	1/11/2019		Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Inspection summary of experts from National Institute for Food and Drug Control, Center for Drug Evaluation, Zhejiang Food and Drug Administration etc. between Jan. 10-Jan. 11, 2019

66	CHEN_Baozhenn	CHEN_Baozhenn					20190110-专家信息澄清汇总表.docx	7/16/2019	7/16/2019	Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Inspection summary of experts from National Institute for Food and Drug Control, Center for Drug Evaluation, Zhejiang Food and Drug Administration etc. between Jan. 10-Jan. 11, 2019
67	CHEN_Baozhenn	CHEN_Baozhenn					2018.12.14关于境内境外媒体利用公司FDA警告信进行不实报道的专题报告（台州市委市政府）.docx	12/17/2018	12/17/2018	Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	A report to Taizhou municipal government regarding public sentiment
68	CHEN_Baozhenn	CHEN_Baozhenn					20180728(4)临海市政府--关于华海药业缙沙坦事件有关情况的续报.doc	7/29/2018	7/29/2018	Microsoft Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	A report to Taizhou municipal government regarding valsartan event
69	CHEN_Baozhenn	CHEN_Baozhenn					20190107台州市市场监督管理局汇报材料(1).doc	1/7/2019	1/9/2019	Microsoft Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	A report to Taizhou Administration for Market Regulation regarding valsartan event
70	CHEN_Baozhenn	CHEN_Baozhenn					2018.10.24报临海市政府.docx	11/5/2018	11/5/2018	Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	A report to Taizhou municipal government regarding valsartan event
71	CHEN_Baozhenn	CHEN_Baozhenn YE_Cunxiao					2018.07.20关于缙沙坦氢氯噻嗪胶囊主动召回进展情况的报告-重庆康刻尔制药.pdf	7/20/2018	7/22/2018	Portable Document Format	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Report from Chongqing KangKeEr to Chongqing Food and Drug Administration regarding the recall of valsartan of ZHP
72	CHEN_Baozhenn	CHEN_Baozhenn					客户诉求总结.docx	7/22/2018	7/22/2018	Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	A summary of communications with the Medical Products Administration authorities of Shandong Province and Jiangsu Province
73	CHEN_Baozhenn	CHEN_Baozhenn YE_Cunxiao					关于请报送华海药业缙沙坦原料药及相关制剂批号的函.pdf	8/10/2018	4/10/2020	Portable Document Format	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Letter from National Food and Drug Administration to the local Food and Drug Administration of Heilongjiang, Jiangsu, Zhejiang, Shandong, Hainan, Chongqing regarding NDMA risk of valsartan API
74	CHEN_Baozhenn	CHEN_Baozhenn					Microsoft_Word__4.docx	9/27/2019		Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Meeting minutes with National Drug Administration regarding inspection

75	DONG_Peng	DONG_Peng ZHOU_Ting	Ada Zhou <adazhou@huahaipharm.com>	董鹏 <dongpeng@huahaipharm.com>		Pw: 华海药业关于厄贝沙坦原料药的答复.eml	5/27/2019				RFC822 Email Message	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Email to Center of Drug Administration in reply to the question raised by CDE regarding irbesartan API
76	LI_Qiangming	GU_Eric LI_Qiangming	mawang@huahaipharm.com	李强明 <liqiangming@huahaipharm.com> 顾虹总 <hgu@syncores.net>		Pw: 转发：关于协助药审中心起草《药物中亚硝酸盐杂质研究技术指导原则》研讨会的邀请	11/15/2019				RFC822 Email Message	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Email from Center of Drug Administration to ZHP regarding of NDMA in drugs research technical guideline, in which ZHP was told to keep confidential.
77	LI_Qiangming	GU_Eric LI_Qiangming									Portable Document Format	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	A guideline for the study of nitrosamine impurities in drugs from Center for Drug Evaluation (CDE) of the China National Medical Products Administration, in which the CDE expressly required ZHP to keep confidential.
78	YE_Cunxiao	YE_Cunxiao									Microsoft Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	A report intended to Taizhou municipal government regarding valsartan event.
79	YE_Cunxiao	YE_Cunxiao									Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	A document dated Oct 22, 2018 of ZHP regarding valsartan event, intended for Taizhou municipal government
80	YE_Cunxiao	YE_Cunxiao									Microsoft Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	A report intended to Taizhou municipal government regarding valsartan event by Linhai municipal government
81	YE_Cunxiao	YE_Cunxiao									Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	A report to Zhejiang Medical Products Administration regarding progress of rectification and plan for next stage
82	YE_Cunxiao	YE_Cunxiao									Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	A report to Taizhou Commerce Bureau regarding the import ban of ZHP product by EU and USA.
83	YE_Cunxiao	YE_Cunxiao									Microsoft Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	A report to Zhejiang Medical Products Administration regarding valsartan event in EU and USA

84	Guo_Xiaodi	Guo_Xiaodi					2017年6月12日CDE与华海集团交流情况纪要_June_302017--CDE修改.docx	7/30/2017	7/30/2018	Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Meeting minutes between ZHP and the officials from Center of Drug Evaluation regarding dissolution test and exemption of products dated June 12, 2017
85	ZHU_Wenquan	ZHU_Wenquan					台州药检所、临海局对厄贝沙坦基因毒杂质事件调研和关注20190108.docx	1/8/2019		Unknown Binary File	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Meeting minutes between ZHP and Taizhou Medical Products Administration regarding genotoxic impurities in irbesartan
86	ZHOU_Ting	ZHOU_Ting				华海模板	会议纪要_厄贝沙坦CDE交流_20190619.docx	7/2/2019	8/15/2019	Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Meeting minutes between ZHP and Center for Drug Administration regarding NDMA event in sartans
87	ZHOU_Ting	ZHOU_Ting					20190619华海厄贝沙坦原料药沟通交流会会议纪要.doc	7/16/2019	8/15/2019	Microsoft Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Art. 27 of Implementing Regulations regarding the State Secrets Protection Law of the People's Republic of China. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	Meeting minutes between ZHP and Center for Drug Administration regarding NDMA event in sartans
88	ZHOU_Ting	ZHOU_Ting					关于缬沙坦杂质的信息_国家局V2_July 11,2018.docx	7/12/2018	8/15/2019	Microsoft 2007 Word Document	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	A report sent to National Food and Drug Administration regarding NDMA in valsartan